Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026.
Q2 2026 key financials · XBRL
- Net income
- −$43M
- −4.8% YoY · −5.2% QoQ
- EPS (diluted)
- −$0.39
- +15.2% YoY · −5.4% QoQ
Source: XBRL data from the Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2026 10-Q on SEC EDGAR. USD.
Amylyx Pharmaceuticals, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue not reported; operating expenses $45.7M vs $42.9M YoY, up 7%
- Net loss $43.4M vs $41.4M YoY, up 5%; operating margin not applicable
- Avexitide R&D $9.4M, up 32% YoY; AMX0035-PSP R&D $36K, down 99%
- Cash, equivalents and marketable securities $250.8M at June 30, 2026; funding expected into 2028
- LUCIDITY topline data expected Q3 2026; potential avexitide launch targeted for 2027
Risk Factors
- Newly expanded geopolitical and policy risk: U.S. government regulatory activity, conflicts involving Iran, Ukraine, and the Middle East, plus inflation and interest-rate changes
- Most material operational change: avexitide LUCIDITY enrollment completed, with topline data expected in Q3 2026 and potential launch in 2027
- Regulatory and compliance risk: OBBBA changes to R&D tax treatment and Medicaid, Medicare, and Marketplace eligibility could reduce cash flow and patient populations
- Market risk: AMX0035 ALS revenue ended after RELYVRIO/ALBRIOZA withdrawal following PHOENIX failure to meet primary and secondary endpoints
- Financial risk: $836.1 million accumulated deficit and no committed additional capital source, despite funding expected into 2028
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amylyx Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.